Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers:Feasible or not feasible?  

作　　者：Jian-Qiang Chen Xiang Lan 

机构地区：[1]Department of Hepatobiliary Surgery,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China

出　　处：《World Journal of Gastroenterology》2025年第10期134-138,共5页世界胃肠病学杂志(英文)

摘　　要：A clinical trial of nab-paclitaxel plus capecitabine as a first-line treatment for advanced biliary tract cancers was conducted.We analyzed the development of systemic therapy recommended by the National Comprehensive Cancer Network guidelines and the development of nab-paclitaxel combination chemotherapy for advanced biliary tract cancers(BTCs)and concluded that nab-paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs.

关 键 词：NAB-PACLITAXEL CAPECITABINE Biliary tract cancers Systemic therapy Firstline regimen 

分 类 号：R735.8[医药卫生—肿瘤]